The NCR included a total of 28,120 patients with lung cancer in the study period, of whom a total of 1185 patients were selected (Fig. 1) with stage IV KRAS-positive adenocarcinoma of the lung, being treated with first-line immunotherapy or combination chemoimmunotherapy. This evidence concerns the gene KRAS and lung cancer.